GlassScriptPhysician profile
Shahira Halim
NPI 1124796941
$2,493.81
in general payments reported to CMS, 2019-2025
22 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $1,350 · 2023: $325 · 2024: $163 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $429.00 | 2021-2025 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $396.21 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $242.82 | 2021-2025 | Fasenra, Breztri, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.02 | 2021-2022 | |
| Electromed, INC. | $152.69 | 2022-2025 | Smartvest |
| Philips North America LLC | $134.89 | 2021-2022 | |
| Genzyme Corporation | $127.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $108.05 | 2022-2025 | Zerbaxa, Dificid |
| Actelion Pharmaceuticals US, INC. | $92.25 | 2021-2022 | |
| Inogen, INC. | $75.24 | 2022-2025 | |
| Baxter Healthcare | $75.06 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $73.73 | 2022-2023 | Xolair |
| Mylan Specialty L.P. | $69.97 | 2021-2022 | |
| Amgen INC. | $61.74 | 2022-2025 | Tezspire |
| Advanced Respiratory, INC | $56.13 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $47.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.37 | 2024 | Glassia |
| Novartis Pharmaceuticals Corporation | $28.33 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $27.58 | 2022 | |
| United Therapeutics Corporation | $22.12 | 2023 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $21.23 | 2024 | Lumryz |
| Scpharmaceuticals INC. | $19.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahira Halim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.